 In naive chemotherapy tumor-KRAS wild-type metastatic colorectal cancer patients, who are BEAMing positive KRAS mutated in blood before treatment may have worse evolution in terms of PFS progression Free Survival and response rate than BEAMing negative KRAS native in blood patients. 